Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identifying the intramuscular dose equivalent to the 4mg
intravenous dose and assess its safety and tolerability as a weekly injection.
Phase:
Phase 1
Details
Lead Sponsor:
University of Arizona University of Southern California
Collaborators:
Alzheimer's Association University of Arizona University of Southern California